Vyvgart market outlook improves as autoimmune demand rises
The Business Research Company says the Vyvgart market is set for further growth as autoimmune disease cases climb and use of FcRn inhibitors expands. North America led the market in 2025, while the company expects broader indications and more precision-immunology adoption to shape the next phase.
Why it matters: - Rising autoimmune disease prevalence is expanding the potential patient base for Vyvgart, a treatment used for certain autoimmune disorders including generalized myasthenia gravis. - Growth in specialty neurology care and targeted biologic treatments is helping push the market beyond its initial use case. - The market outlook matters for drug developers, clinicians and investors watching FcRn inhibitor adoption and long-term disease management trends.
What happened: - The Business Research Company released a new Vyvgart market forecast on November 20, 2026. - The report says the Vyvgart market is gaining traction as autoimmune disease treatment advances continue. - The company expects the market to grow further as Vyvgart indications expand beyond generalized myasthenia gravis. - North America held the largest share of the Vyvgart market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.
The details: - Vyvgart, or efgartigimod alfa-fcab, is designed to treat certain autoimmune disorders, especially generalized myasthenia gravis, a rare condition marked by muscle weakness. - The drug targets the neonatal Fc receptor, or FcRn, which helps maintain levels of harmful antibodies. - By blocking FcRn, Vyvgart reduces pathogenic antibodies, which can improve muscle strength and reduce fatigue. - Historic growth in the market is tied to a better understanding of autoimmune pathways, approvals for innovative biologics, rising diagnosis rates of generalized myasthenia gravis, broader access to specialty neurology care and availability of advanced antibody therapies. - The company says future growth will also be driven by broader adoption of precision immunology treatments, rising investment in autoimmune biologics, higher demand for long-term disease management and development of next-generation FcRn inhibitors. - Expected trends include increased use of FcRn inhibitor therapies, more focus on targeted autoimmune treatments, wider clinical use of antibody reduction strategies, demand for personalized immunotherapy and emphasis on sustained disease control. - The Myasthenia Gravis Foundation of America said in August 2024 that about 150 to 200 people per million globally are affected by myasthenia gravis, with an estimated U.S. prevalence of 37 cases per 100,000 people.
Between the lines: - The forecast points to a broader shift in autoimmune care toward precision therapies that reduce specific antibody activity instead of relying only on broader immunosuppression. - Vyvgart’s commercial potential appears tied to both disease prevalence and the pace at which clinicians adopt FcRn inhibitors across more indications. - North America’s lead suggests the region remains the most established market for specialty autoimmune therapies, even as other regions continue to develop.
What's next: - The company expects the Vyvgart market to keep expanding as indications broaden and precision immunology adoption increases. - New report features for 2026 include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis. - The report package also includes updated graphics and tables.
The bottom line: - Vyvgart’s outlook is improving because demand for targeted autoimmune treatments is rising and the drug’s market may widen beyond generalized myasthenia gravis.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Business Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.